Carregant...
What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review
BACKGROUND: Psilocybin is a predominant agonist of 5HT(1A) and 5HT(2A/C) receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedeli...
Guardat en:
| Publicat a: | Porto Biomed J |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams & Wilkins
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8055489/ https://ncbi.nlm.nih.gov/pubmed/33884324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/j.pbj.0000000000000128 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|